Alixorexton

Alixorexton (INNTooltip International Nonproprietary Name; developmental code name ALKS-2680) is an orexin receptor agonist which is under development for the treatment of sleep disorders, including narcolepsy and idiopathic hypersomnia.^[1][2][3] Alixorexton is being developed by Alkermes^[4] As of July 2025, it is in phase 2 clinical trials with planned advancement to a phase 3 study for the treatment of narcolepsy type 1.^[4]

Alixorexton

Clinical data
Other names	ALKS-2680; ALKS2680
Routes of administration	Oral
Drug class	Orexin OX2 receptor agonist
Identifiers
IUPAC name N-[(15S,16R)-10-oxo-8,18-dioxa-11-azatetracyclo[17.2.2.02,7.011,16]tricosa-2,4,6-trien-15-yl]methanesulfonamide
CAS Number	2648347-56-0
PubChem CID	156417714
IUPHAR/BPS	13879
UNII	3BRW4ARU66
Chemical and physical data
Formula	C21H30N2O5S
Molar mass	422.54 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C1N2CCC[C@@H]([C@@H]2CO[C@@H]3CC[C@@H](CC3)C4=C(OC1)C=CC=C4)NS(=O)(C)=O
InChI InChI=InChI=1S/C21H30N2O5S/c1-29(25,26)22-18-6-4-12-23-19(18)13-27-16-10-8-15(9-11-16)17-5-2-3-7-20(17)28-14-21(23)24/h2-3,5,7,15-16,18-19,22H,4,6,8-14H2,1H3/t15?,16?,18-,19-/m0/s1 Key:IHNJMACFBQEKRJ-VHZYLWGESA-N

See also

• Orexin receptor § Agonists
• List of investigational sleep drugs § Orexin receptor agonists